H Plus Yangji Hospital
Seoul, South Korea
NCT Number: NCT07717749
A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 Under Fasted Conditions in Healthy Adult Subjects
Trial opening soon.
Get Notified19 year–64 year
All sexes
Interventional
Phase 1
Seoul, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Single-dose oral administration of AD-118, according to randomized treatment sequence in a 2-period crossover design.
Time frame: [Time Frame: pre-dose (0hour) to 36hours]
AUCt of AD-118
Time frame: Time Frame: pre-dose (0hour) to 36hours]
Cmax of AD-118
Contact information is provided by the study sponsor or research team.
Addpharma Inc.
Industry
An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-118 Compared to AD-1181 in Healthy Adult Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07686536
Chronic Heart Failure
View Trial DetailsNCT07647848
Acute Decompensated Heart Failure, Chronic Heart Failure
View Trial DetailsNCT07628777
Chronic Heart Failure, Heart Failure With Preserved Ejection Fraction (HFpEF)
Xi’an, Shanxi, China
View Trial DetailsNCT07476157
Chronic Heart Failure
Seoul, South Korea
View Trial Details